Bluebird Bio intends to split into two companies, but for now, its troubles are also divided
Splitting Bluebird Bio into two publicly traded companies is the best fix for the biotech’s recent struggles, CEO Nick Leschly said.
Read The StoryBiotech
Inside the discoveries, personalities, and deals driving drug development. Sign up for The Readout newsletter to get the latest on biotech delivered to your inbox. And subscribe to STAT+ to access daily, market-moving coverage of the biotech sector — from startup funding to clinical trial readouts
How nanotechnology helps mRNA Covid-19 vaccines work
Lilly’s preliminary Alzheimer’s data adds $4 billion to Biogen’s value
Eli Lilly says drug slowed Alzheimer’s decline in preliminary study
After repeated FDA rejections, key investor writes down stake in former diabetes unicorn Intarcia Therapeutics
All Coverage
advertisement
